Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)
Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges), Chris Venner(BC Cancer Agency), Philip N. Hawkins(The Royal Free Hospital), Raymond L. Comenzo(Tufts Medical Center), Murielle Roussel(Centre Hospitalier Universitaire de Limoges), Olivier Decaux(Centre Hospitalier Universitaire de Rennes), Pierre Morel(Institut für Gießereitechnik), David Lavergne, M. Macro(Centre Hospitalier Universitaire de Caen Normandie), Ashutosh Wechalekar(University College Hospital), Estibaliz Lazaro(Centre National de la Recherche Scientifique), Jean‐Luc Pellegrin(Centre National de la Recherche Scientifique), Frank Bridoux(Université de Poitiers), P. Mercié(Centre National de la Recherche Scientifique), Dania Mohty(Centre Hospitalier Universitaire de Limoges), JD Gillmore(University College London), Parameswaran Hari(Medical College of Wisconsin)
Cited by 129
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
|European Heart Journal|2016|2.5k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines
|European Journal of Heart Failure|2016|1.8k